People using semaglutide for diabetes or weight loss have also reported experiencing a reduced desire for alcohol. A new ...

Nearly two-thirds (64%)  of Americans who have tried weight loss injections report the drugs as being “extremely effective” or “effective.” A pressing question for many users of GLP-1 receptor agonist ...

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

Semaglutide — the active substance in Ozempic and Wegovy — may help reduce alcohol cravings in people with alcohol use ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Researchers at the University of North Carolina found that a once-weekly injection of Ozempic could cut cravings at its lowest dose level.

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to the drug major Sun Pharma Labs to conduct the Phase III ...